Literature DB >> 21120868

Malignancies in the setting of primary immunodeficiency: Implications for hematologists/oncologists.

Ralph S Shapiro1.   

Abstract

Many primary immunodeficiency disorders (PIDD) are associated with elevated risks for different types of cancer. Defective immunosurveillance mechanisms in PIDD and infection with oncogenic viruses (eg, Epstein Barr, herpesvirus 8) seem to have significant contributory roles in many cases. Non-Hodgkin lymphoma and Hodgkin disease are two of the most common PIDD-associated malignancies. The impact of PIDD-associated malignancy has increased in recent years in parallel with improved patient with PIDD survival and longevity, due largely to effective immunoglobulin replacement therapy. Epidemiologic data, clinical patterns, and management considerations of the common PIDD-associated cancers are reviewed.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21120868     DOI: 10.1002/ajh.21903

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  18 in total

1.  Childhood and adolescent lymphoma in Spain: incidence and survival trends over 20 years.

Authors:  R Marcos-Gragera; M Solans; J Galceran; R Fernández-Delgado; A Fernández-Teijeiro; A Mateos; J R Quirós-Garcia; N Fuster-Camarena; V De Castro; M J Sánchez; P Franch; M D Chirlaque; E Ardanaz; C Martos; D Salmerón; R Peris-Bonet
Journal:  Clin Transl Oncol       Date:  2018-04-05       Impact factor: 3.405

2.  T cell inhibitory mechanisms in a model of aggressive Non-Hodgkin's Lymphoma.

Authors:  Tamara Hilmenyuk; Carla A Ruckstuhl; Michael Hayoz; Christian Berchtold; Jean-Marc Nuoffer; Shyam Solanki; Hector C Keun; Paul A Beavis; Carsten Riether; Adrian F Ochsenbein
Journal:  Oncoimmunology       Date:  2017-09-21       Impact factor: 8.110

3.  Cancer vaccines.

Authors:  Margaret A Liu
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-10-12       Impact factor: 6.237

4.  Primary hepatic lymphoma in a patient with previous rectal adenocarcinoma: a case report and discussion of etiopathogenesis and diagnostic tools.

Authors:  Lucia Raimondo; Idalucia Ferrara; Alfonso De Stefano; Chiara Alessandra Cella; Francesco Paolo D'Armiento; Giuseppe Ciancia; Roberto Moretto; Amalia De Renzo; Chiara Carlomagno
Journal:  Int J Hematol       Date:  2012-02-21       Impact factor: 2.490

5.  Asymptomatic incidental neuroblastoma in a patient with SH2D1A deficiency.

Authors:  Taumoha Ghosh; Angela Guerrero-Pena; Madhuri Kashyap; Ali G Saad; Chad M Thorson; Asha B Pillai
Journal:  Pediatr Blood Cancer       Date:  2021-08-29       Impact factor: 3.167

6.  Case Report: Initial Treatment Adjustments and Complications in Ovarian Cancer Patient With Inborn Error of Immunity.

Authors:  Jamila Mammadova; Anna Redden; Rachel Cruz; Maryssa Ellison; Tyra Gatewood; Carla Duff; Anthony Canella; Charurut Somboonwit; Chakrapol Sriaroon; Joseph F Dasso; Terry Harville; Roohi Ismail-Khan; Jolan E Walter; Sumai Gordon
Journal:  Front Oncol       Date:  2022-06-29       Impact factor: 5.738

7.  Genetic predispositions to childhood leukemia.

Authors:  Elliot Stieglitz; Mignon L Loh
Journal:  Ther Adv Hematol       Date:  2013-08

Review 8.  Colorectal Lymphoma: A Review.

Authors:  Nathan D Gay; Andy Chen; Craig Y Okada
Journal:  Clin Colon Rectal Surg       Date:  2018-09-04

9.  The paradigm of hematological malignant versus non-malignant manifestations, driven by primary immunodeficiencies: a complex interplay.

Authors:  C Kelaidi; V Tzotzola; S Polychronopoulou
Journal:  Fam Cancer       Date:  2021-06-15       Impact factor: 2.375

Review 10.  Attending to warning signs of primary immunodeficiency diseases across the range of clinical practice.

Authors:  Beatriz Tavares Costa-Carvalho; Anete Sevciovic Grumach; José Luis Franco; Francisco Javier Espinosa-Rosales; Lily E Leiva; Alejandra King; Oscar Porras; Liliana Bezrodnik; Mathias Oleastro; Ricardo U Sorensen; Antonio Condino-Neto
Journal:  J Clin Immunol       Date:  2013-11-16       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.